Showing results (911-920 of 3,354) with videos related to

Sort By:
Pageof 336
The Lancet. Oncology|October 22, 2011
Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective studyJesus Garcia-Donas, Emilio Esteban, Luis Javier Leandro-García, et al.
The Lancet. Oncology|February 28, 2009
Surrogate endpoints for overall survival in locally advanced head and neck cancer: meta-analyses of individual patient dataStefan Michiels, Aurélie Le Maître, Marc Buyse, et al.
The Lancet. Oncology|December 16, 2011
Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trialDavid Dearnaley, Isabel Syndikus, Georges Sumo, et al.
The Lancet. Oncology|December 20, 2011
Addition of bevacizumab to standard chemoradiation for locoregionally advanced nasopharyngeal carcinoma (RTOG 0615): a phase 2 multi-institutional trialNancy Y Lee, Qiang Zhang, David G Pfister, et al.
The Lancet. Oncology|February 10, 2012
Bone density and structure in healthy postmenopausal women treated with exemestane for the primary prevention of breast cancer: a nested substudy of the MAP.3 randomised controlled trialAngela M Cheung, Lianne Tile, Savannah Cardew, et al.
The Lancet. Oncology|January 24, 2012
Carpal tunnel syndrome and musculoskeletal symptoms in postmenopausal women with early breast cancer treated with exemestane or tamoxifen after 2-3 years of tamoxifen: a retrospective analysis of the Intergroup Exemestane StudyJ Sven D Mieog, James P Morden, Judith M Bliss, et al.
The Lancet. Oncology|September 5, 2008
Effects of anastrozole on cognitive performance in postmenopausal women: a randomised, double-blind chemoprevention trial (IBIS II)Valerie A Jenkins, Laurence M Ambroisine, Louise Atkins, et al.
The Lancet. Oncology|September 21, 2007
COX-2 expression predicts prostate-cancer outcome: analysis of data from the RTOG 92-02 trialLi-Yan Khor, Kyounghwa Bae, Alan Pollack, et al.
The Lancet. Oncology|March 30, 2012
Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trialKim Margolin, Marc S Ernstoff, Omid Hamid, et al.
The Lancet. Oncology|February 8, 2022
Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trialMatthew R Smith, Howard I Scher, Shahneen Sandhu, et al.
Pageof 336